Ursodeoxycholic Acid Market Applications, SWOT Analysis, and Growth Trends Report
Global Ursodeoxycholic Acid Market is anticipated to grow at a CAGR of 7% in the forecast period owing to the developments occurring worldwide and changing demand from patients. Global Ursodeoxycholic Acid Market is anticipated to grow at a CAGR of 7% in the forecast period owing to the developments occurring worldwide and changing demand from patients. Ursodeoxycholic acid is a steroid bile acid used for treating liver disorder. It naturally occurs in form of bile acid and is used to liquefy gallstones, which are rich in cholesterol. It also helps in improving the bile flow in primary biliary cirrhosis.
Ursodeoxycholic acid dissolves the cholesterol rich gallstones that accumulate due to cholesterol deposit. The acid helps prevent gallstone formation in patients
Ursodeoxycholic acid also treats liver related symptom of cystic fibrosis, which is mostly present in children of 6-18 years of age. However, few symptoms may hamper the growth of ursodeoxycholic acid market. These symptoms comprise headache, diarrhea, hair loss, indigestion, vomiting or nausea, backache, unusual bleeding or bruising, cloudy and bloody urine, fever and cough, tarry or black stools, painful and/or frequent urination, swelling of lips, eyelids, tongue and face.
The market is categorized on the basis of product type, applications, and geography. On the basis of product type, market is divided into synthetic ursodeoxycholic acid and extraction ursodeoxycholic acid. Based on applications, market is divided into pharmacy and health products.
Geographically, market is segmented as North America, Europe, Asia Pacific, and RoW (Rest of the World). Asia Pacific is expected to hold the largest share of ursodeoxycholic acid market owing to the rise in liver diseases and rising elderly population in the region.
The key players in ursodeoxycholic acid market include ICE, Mitsubishi Tanabe Pharma, Arcelor Chemicals, Daewoong Chemical, Erregierre, Dipharma Francis, PharmaZell GmbH, Suzhou Tianlu, Grindeks, Abil Chempharma, Biotavia Labs, and Zhangshanbelling.
Firma: Million Insights
Ansprechpartner: Tom Clark
Die PresseMitteilung stellt eine Meinungsäußerung des Erfassers dar. Der Erfasser hat versichert, dass die eingestellte PresseMitteilung der Wahrheit entspricht, dass sie frei von Rechten Dritter ist und zur Veröffentlichung bereitsteht. businesspress24.com macht sich die Inhalte der PresseMitteilungen nicht zu eigen. Die Haftung für eventuelle Folgen (z.B. Abmahnungen, Schadenersatzforderungen etc.) übernimmt der Eintrager und nicht businesspress24.com